May2022
RevitalVision at the AAO 2022 mid year press relase
March 2022
New randomized controlled trial on RevitalVision
Effects of Perceptual Learning on Deprivation Amblyopia in Children with Limbal Dermoid: A Randomized Controlled Trial
The study compared 2 groups of children with amblyopia after corneal transplant : One group received standard patching therapy and the second group received patching + RevitalVision.
The group that underwent RevitalVision therapy experienced statistically significant improvement in vision.
Read the full study
March 2022
RevitalVision will present at the AAPOS 2022 – Arizona
2022 Annual Meeting of the American Association for Pediatric Ophthalmology and Strabismus (AAPOS), on March 23-27, 2022.
RevitalVision at HIMSS 22
This year, the Israel Export Institute together with the Foreign Trade Administration – Ministry of Economy & Industry will present 18Israeli Digital Health companies. And we are proud to be amongst these innovative companies
November 2021
RevitalVision on The Ophthalmologist
Yair Yahav, CEO and founder of RevitalVision, was interviewed in The Ophthalmologist about how we improve vision in adult amblyopia
July 2021
RevitalVision received reimbursement code in the USA
RevitalVision is a standalone therapeutic vision training software, the only FDA-approved product for market, and clinically proven to improve vision in adult amblyopia (age 9-plus), received a unique Current Procedural Terminology (CPT) reimbursement code from the American Medical Association (AMA).
